ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines to address unmet medical needs in cancer patients. The company specializes in developing and commercializing targeted cancer therapies for non-small-cell lung cancer and other solid tumors. Its lead development candidate is furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor currently undergoing Phase 3 clinical trials for the treatment of non-small-cell lung cancer patients. The company also develops ARR-002 and maintains strategic collaborations with Aarvik Therapeutics Inc. ArriVent BioPharma was incorporated in 2021 and is headquartered in Newtown Square, Pennsylvania.
| Symbol | AVBP |
|---|---|
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| CEO | Zhengbin Yao |
| Employees | 77 |
| Headquarters | Newtown Square, PA, US |
| IPO | 2024-01-26 |
| Website | arrivent.com |